suppressing function in inhibiting cell proliferation, invasion and migration.
INTRODUCTION AND OBJECTIVES: Circular RNAs (circRNAs) represent a class of endogenous noncoding RNAs that have recently been recognized as important regulators of gene expression and pathological networks. However, the characterization and function of circRNAs in primary metastatic clear cell renal cell carcinoma (ccRCC) remain elusive.
METHODS: We investigated the expression profile of circRNAs in five primary metastatic and five non-metastatic ccRCC tumor samples using a high-throughput circRNA microarray. Bioinformatic analyses were applied to study these differentially expressed circRNAs. Furthermore, qRT-PCR was performed to confirm these results. The circ-FOXM1 expression levels as well as clinicopathological significance were evaluated in primary RCC clinical specimens and RCC cell lines. In vitro knockdown of circ-FOXM1 in RCC cell lines was used to determine its effect on cellular proliferation, migration, and invasion.
RESULTS: Here we identified 528 differentially expressed circRNAs in primary metastatic ccRCC as compared with primary nonmetastatic ccRCC, of which 282 were significantly upregulated and 246 were downregulated. Differential circRNAs expression between the two groups were validated by qRT-PCR assay. Bioinformatics was employed to predict the interaction of circRNAs and mRNAs in metastatic ccRCC. We further characterized one circRNA hsa_circ_0025036 derived from the FOXM1 gene and termed it as circ-FOXM1. The expression of circ-FOXM1 is often upregulated in primary metastatic ccRCC as compared with primary non-metastatic ccRCC. The level of circ-FOXM1 was observed as an independent prognostic marker for overall survival of patients with ccRCC. Moreover, circ-FOXM1 promotes migratory, invasive, and metastasis capacities of ccRCC cells.
CONCLUSIONS: Overall, the differential expression of multiple circRNAs and their clinical significance in metastatic ccRCC tissues as revealed by our study suggests that circ-FOXM1 is a novel metastatic factor and prognostic marker in ccRCC, we propose that circRNA-FOXM1 could be used as a potential target in metastatic ccRCC therapy. or TSC2 causes tuberous sclerosis, a multisystem genetic syndrome that can lead to formation of benign tumors in the kidneys, lungs, and other organs and has also been linked to epilepsy and autism. The tumor suppressors Tsc1 and Tsc2 form the tuberous sclerosis complex (TSC), a regulator of mTOR activity. Tsc1 stabilizes Tsc2; however the precise mechanism remains elusive. Molecular chaperones such as heat shock protein-90 (Hsp90) are essential for the stability and activation of numerous signaling proteins, including tumor suppressors. The objective of this work was to determine the role of Hsp90 in the stability and activity of TSC. We hypothesize that Hsp90 mediates TSC formation and thus is essential for the stability of Tsc2.
Source of
METHODS: Tsc1-FLAG and Tsc2-FLAG were transiently expressed and isolated from HEK293 cells. Interacting proteins were identified by co-immunoprecipitation. Hsp90 chaperone function is coupled to its ATPase activity. We have developed an assay to measure this activity by determining the rate of ATP breakdown and inorganic phosphate production. Hsp90 was isolated from WT and TSC1-/-mice and assayed for ATPase activity in vitro.
RESULTS: Tsc2 interacts with the molecular chaperone Hsp90 both in vitro and in vivo. Treatment of HEK293 cells with Hsp90 inhibitors such as ganetespib or SNX2112 caused ubiquitination and proteasomal degradation of Tsc2; therefore Tsc2 is a new client of Hsp90. However, Tsc1 stability does not depend on Hsp90. Tsc1 potently decelerates Hsp90 ATPase activity and facilitates the interaction of Tsc2 and other clients with Hsp90. We also showed that Tsc1 competes with the activating co-chaperone Aha1 for binding to Hsp90, providing a reciprocal regulatory mechanism for chaperoning of kinase and non-kinase clients.
CONCLUSIONS: Tsc1 interacts with Tsc2 and protects Tsc2 from degradation. Many pathogenic mutations of Tsc2 destabilize the protein. Our data suggest that lack of interaction of pathogenic Tsc2 mutants with Tsc1 and consequently Hsp90 lead to their degradation. Further, these newly elucidated roles of Tsc1 and Tsc2 suggest a potential mechanism for the observed differences between TSC1 and TSC2 mutant disease. In the absence of Tsc2, Tsc1 will still perform its critical role as a co-chaperone of Hsp90. However when Tsc1 is lost, the stability of both Tsc2 and many other Hsp90 clients is dramatically reduced, leading to a different phenotypic manifestation. 
MP88-14 CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS
Kazuyuki Numakura*, Akita, Japan; Jesse Novac, Jean-Christophe Pignon, Toni Choueiri, Sabina Signoretti, Boston, MA INTRODUCTION AND OBJECTIVES: Previous studies have shown that treatment with an mTOR inhibitor (mTORi) is effective against renal cell carcinomas (RCCs), but with limited efficacy and durability. The concept of a cancer stem cell may explain treatment failures in advanced RCCs, but there is no evidence to support this, especially regarding mTORi resistance. Notch, which converts aldehydes to carboxylic acids in the cell membrane, may contribute to the generation of a drug-tolerant tumor cell population. In this study, the relationship between cancer stem cell characteristics and Notch activity was assessed in RCC cells with acquired resistance to mTORi.
METHODS showing resistance to mTORi. Cancer stem cell characteristics were confirmed by tumor sphere-formation assay and aldehyde dehydrogenase activity. Stem cell inducible pathways were screed by qRT-PCR and western blotting, and activations of Notch related signal components were confirmed. Specific Notch inhibitor, MK0752, showed marked inhibition of tumor sphere formation (Figure 1 ) and cell proliferation (Figure 2 ) of established cell, not of primary cell.
CONCLUSIONS: Cancer stem cell characteristics in RCCs may be involved in the mechanism underlying the acquisition of resistance to EVE as shown in this study. Furthermore, Notch could assume a role of maintaining these characteristics and is therefore a potential target for the treatment of mTORi-resistant RCCs. progressed to a locally advanced disease state or exhibit metastases. cAMP responsive element binding protein 1 (CREB1) is a proto-oncogene in various cancer. This study was to explore the function and clinical significance of phosphorylated cAMP responsive element binding protein 1 (p-CREB1) at Ser 133 site in advanced ccRCC. The CREB1 phosphorylate pathway may be a novel target for kidney therapy.
METHODS: The expression of p-CREB1 (Ser133) and non p-CREB1 (Ser133) is determined by immunohistochemistry (IHC) in 151 advanved ccRCC patients. Through constructing lentiviral vector and using small molecular inhibitor, 666-15, the phosphorylated CREB (Ser133) are knockdown, overexpressed and inhibited. The proliferation of 786-0 cells in vitro and in vivo was determined by clone formation assay, MTS assay, and subcutaneous tumor formation in nude mice. To investigate the mechanisms, the interacting proteins of CREB1 were precipitated by pull-down assay and identified by mass spectrum. Then the proteins interaction was confirmed by co-immunoprecipitation in kidney cancer cells. Protein and mRNA expression level were measured by western blot and qPCR, respectively.
RESULTS: P-CREB1 (Ser133) and non p-CREB1 (Ser133) is highly expressed in ccRCC tissues. In multi-factor regression analysis, p-CREB1 (Ser133) is an independent risk factor but not non p-CREB1. The clone formation and proliferation ability is inbibted by phosphorylated CREB1 (Ser133) knockdown and 666-15, however, reversed by CREB1 (Ser133) overexpression. And subcutaneous tumor in nude mice is significantly shrinked by treating with 666-15.The interaction of CREB1 with serine/threonine-protein kinase 1 (SRPK1) and casein kinase II subunit beta (CSNK2B) were identified and confirmed in kidney cancer cells. The expression of p-CREB1 (Ser133) protein was higher in SRPK1 and CSNK2B overexpressed cells.Knockdown SRPK1 and CSNK2B, the p-CREB1 (Ser133) protein was decreased, the proliferation and migration ability were attenuated, and the cell apoptosis was induced in kidney cancer cells.
CONCLUSIONS: Highly expressed p-CREB (Ser133) is an independent risk of ccRCC patient. CREB1 was activated by SRPK1 and CSNK2 through phosphorylation. Target CREB1 phosphorylate pathway may inhibit the cancer phenotype of ccRCC. METHODS: RCC and its paired normal kidney tissues were immunohistochemically stained for RASAL2 expression. Databases downloaded from TCGA or GEO were used to analyze the methylation status of RASAL2 and the correlation between RASAL2 and c-FOS or VEGFA in RCC tissues. In vitro, RASAL2 gain-function in 786-O cells or loss-function in ACHN cells were measured for the recruitment and tube formation of human umbilical vein endothelial cell (HUVEC) by HUVEC migration assay and tube formation assay, ELISA assay and western blot analysis. In vivo, subcutaneous xenografts in nude mice were used to detect tunorigenicity. Moreover, the expression of RASAL2, VEGFA and CD31 in RCC tissues and xenografts were detect by immunohistochemical (IHC) staining.
RESULTS: The expression of RASAL2 was downregulated in RCC tissues, and RASAL2 mRNA was inversely correlated with
